Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright

Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $18.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 272.67% from the stock’s current price.

Separately, StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Thursday, December 19th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Up 3.2 %

Shares of VNDA opened at $4.83 on Monday. The firm has a market capitalization of $281.63 million, a PE ratio of -17.25 and a beta of 0.76. Vanda Pharmaceuticals has a 12-month low of $3.46 and a 12-month high of $6.75. The stock’s fifty day simple moving average is $4.86 and its 200-day simple moving average is $5.21.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at approximately $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $40,000. SG Americas Securities LLC bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth approximately $61,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at $75,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.